Literature DB >> 9745077

Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer?

T Tsunoda1, Y Yamamoto, M Kimoto, H Imai, S Iwamoto, S Kawasaki, K Kawashima, Y Tadaoka, T Majima, E Onuma, K Iki, T Kubozoe, T Eto.   

Abstract

To determine the tumor size that constitutes early pancreatic cancer, we reviewed and analyzed the English-language and Japanese literature (a total of 25 publications) on small pancreatic cancers less than 2 cm in diameter and/or stage 1 cancers. Reports on in situ carcinoma and intraductal carcinoma of the pancreas were also evaluated. The results were: (1) A total of 302 cases of small pancreatic cancer less than 2 cm in diameter reported at separate institutions were pooled from 15 reports. The rates for patients in stage I and those with no lymph node metastasis averaged 41.7% and 57.9%, respectively. The 5-year postoperative cumulative survival rate (5Y-PCR) was less than 50% in almost all these reports. Similar data were shown in the 7 collective reviews. (2) Another 33 cases of small pancreatic cancer of 1 cm or less in diameter were collected from three reports. The rates for stage I tumor and 5Y-PCR at one institution with two reports were 100% and 100% and the rates in the other report were 85% and 78%, respectively. (3) Twelve cases of in situ carcinoma and intraductal carcinoma of the pancreas were collected from four reports. All of the patients were stage I and were alive with no evidence of tumor recurrence for periods ranging from 6 to 78 months. Small pancreatic cancer less than 1 cm in diameter is better viewed as an early pancreatic cancer, and in situ carcinoma and intraductal carcinoma of the pancreas with minimal invasion to the pancreatic parenchyma may be defined as early pancreatic cancer, regardless of size.

Entities:  

Mesh:

Year:  1998        PMID: 9745077     DOI: 10.1007/s005340050022

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  7 in total

1.  Synthesis and assessment of ZD2-(68Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer.

Authors:  Songqi Gao; Jingcan Qin; Olga Sergeeva; Maxim Sergeev; Peter Qiao; Sarah Roelle; Norbert Avril; Zhenghong Lee; Yajuan Li; Zhengrong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

Review 2.  Imaging in pancreatic disease.

Authors:  Julien Dimastromatteo; Teresa Brentnall; Kimberly A Kelly
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-09       Impact factor: 46.802

3.  Efficacy of repeated cytology of pancreatic juice obtained by endoscopic nasopancreatic drainage tube for early diagnosis of pancreatic cancer: a case series including a case of carcinoma in situ.

Authors:  Shin Kato; Moriya Zakimi; Koki Yamada; Kenji Chinen; Tomiaki Kubota; Masayuki Arashiro; Kaoru Kikuchi; Takahiro Murakami; Fumihito Kunishima
Journal:  Clin J Gastroenterol       Date:  2015-07-26

4.  Long-term survival and prognostic indicators in small (<or=2 cm) pancreatic cancer.

Authors:  Supot Pongprasobchai; Rahul Pannala; Thomas C Smyrk; William Bamlet; Suresh Pitchumoni; Andrei Ougolkov; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Pancreatology       Date:  2008-10-13       Impact factor: 3.996

5.  Pancreatic Duct Stricture That Rapidly Progressed to Pancreatic Ductal Adenocarcinoma and Formed a Mass within 3 Months: A Case Report.

Authors:  Shin Kato; Kenji Chinen; Susumu Shinoura; Fumihito Kunishima
Journal:  Case Rep Gastroenterol       Date:  2018-06-05

6.  Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer.

Authors:  Kee Wook Jung; Myung Hwan Kim; Tae Yoon Lee; Seunghyun Kwon; Hyoung Chul Oh; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

7.  Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.

Authors:  Peter Qiao; Nadia R Ayat; Amita Vaidya; Songqi Gao; Wenyu Sun; Samuel Chou; Zheng Han; Hannah Gilmore; Jordan M Winter; Zheng-Rong Lu
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.